Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma Plc LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 79.00p 0 08:00:00
Bid Price Offer Price High Price Low Price Open Price
78.00p 80.00p 79.00p 79.00p 79.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -6.01 -11.90 34.6

Destiny Pharma (DEST) Latest News

More Destiny Pharma News
Destiny Pharma Takeover Rumours

Destiny Pharma (DEST) Share Charts

1 Year Destiny Pharma Chart

1 Year Destiny Pharma Chart

1 Month Destiny Pharma Chart

1 Month Destiny Pharma Chart

Intraday Destiny Pharma Chart

Intraday Destiny Pharma Chart

Destiny Pharma (DEST) Discussions and Chat

Destiny Pharma Forums and Chat

Date Time Title Posts
30/4/201921:40Destiny Pharma plc37

Add a New Thread

Destiny Pharma (DEST) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Destiny Pharma trades in real-time

Destiny Pharma (DEST) Top Chat Posts

DateSubject
25/5/2019
09:20
Destiny Pharma Daily Update: Destiny Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DEST. The last closing price for Destiny Pharma was 79p.
Destiny Pharma Plc has a 4 week average price of 77p and a 12 week average price of 69p.
The 1 year high share price is 125p while the 1 year low share price is currently 61p.
There are currently 43,815,195 shares in issue and the average daily traded volume is 4,198 shares. The market capitalisation of Destiny Pharma Plc is £34,614,004.05.
05/10/2018
11:54
edmonda: new analysis on pipeline's development and expansion, with increased fair value as a result (a multiple of current share price). Plenty of news expected in coming weeks, too. Note freely accessible here: https://www.equitydevelopment.co.uk/edreader/?ltkn=5f3dec7ebec4cbdaf80bd7d872a074b0AvbosF0F&d=%3D%3DAO4QjM
02/10/2017
14:47
jonwig: At the risk of being a boor, I'll repeat my post #7 from four weeks ago: I saw the initial RNS and looked at the website. Basically their compounds appear to act so quickly that bacteria have no time to develop resistance via mutation. My immediate reaction to this was extreme scepticism. It appears to suggest that antibiotic resistant mutations happen when bacteria are stimulated by exposure to an agent. But this isn't the case: they happen purely randomly. Indeed there will already exist resistant strains, and resistant populations will develop and increase by natural selection as happens with current antibiotics. I met a biochemist last week (on holiday) whose discipline is immunology, so not quite the same, and he confirmed that my general understanding was correct. Obviously I need to do more study on this and it would be good to see if the company's research has been peer-reviewed. (A lot of these companies don't allow that.) I know their early trials have been successful, and I may be off-beam here, but I wouldn't want to invest in anything I didn't understand. I just can't find any corroborative information about their compounds (Help anyone?), and first results should be some time away. (How much?) Until then, it's unlikely the share price will do more than respond to speculative froth. A trigger will be phase results, and it's unlikely these can leak as they should be double-blind and reported immediately. When they are, how many here will understand them? More to the point, they seem to have £14m cash with a burn of £2m pa (but that will increase). At least they won't have to scramble.
Destiny Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
DEST
Destiny Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190525 09:25:34